Get Email Alerts
* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and
R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00
beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in
2011. NHLBI Competing Research Project Grant Applications:* Fiscal Years 2001–2011Number Reviewed and Awarded
Number Reviewed and Awarded and Percent Funded * Includes R01, U01, P01, R03, R15, R21, R29, and R37; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011. Percent of Reviewed Applications Funded (Success Rate)
NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2001–2011
* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other
Research. NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 2001–2011Dollars (Millions)
* Includes RPGs, SBIRs/STTRs, Research
Career Programs, and Other Research. NHLBI Research Project Grants:* Amount Funded by Type of Award, Fiscal Years 2001–2011Dollars (Millions)
* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011. Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 2001–2011Dollars (Thousands)
* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011. NHLBI Research Project Grants:* Average Costs, Fiscal Years 2001–2011
* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011. NHLBI Research Project Grants:* Average Costs, Fiscal Years 2001–2011Dollars (Thousands)
*Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; DP1 and R00 beginning in 2008; R34 and U34 beginning in 2010; and UH2 and UM1 beginning in 2011. NHLBI Cooperative Agreements (U01, U10, U19) ProgramsCooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator's specific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.
* Formerly known as Targeted Approaches to Weight
Control for Young Adults. Heart and Vascular Diseases ProgramARIC Neurocognitive Study (ARIC-NCS), Initiated in Fiscal Year 2010The purpose of this study is to determine whether mid-life vascular risk factors and markers of macrovascular and microvascular disease are predictive of dementia, mild cognitive impairment, and cognitive change in a large biracial ARIC cohort. ObligationsFunding History: Current Active Organizations and Grant Numbers
Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007See Chapter 11. Clinical Trials. Cardiovascular Inflammation Reduction Trial, Initiated in Fiscal Year 2011The purpose of this trial is to test the inflammatory hypothesis of atherothrombosis by evaluating whether low-dose methotrexate will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among patients with stable CVD who are at increased risk indicated by persistent elevations of high-sensitivity C-reactive protein. ObligationsFunding History: Current Active Organizations and Grant Numbers
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004The purpose of this trial is to determine whether renal artery stenting adds value to optimal medical therapy in terms of cardiovascular and renal outcomes in individuals with a history of resistant hypertension and/or chronic kidney disease and stenosis (>60%) of one or both renal arteries. The trial is in an extended follow-up phase. ObligationsFunding History: Current Active Organizations and Grant Numbers
Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA), Initiated in Fiscal Year 2009The purpose of this trial is to determine whether percutaneous left atrial catheter ablation is superior to current pharmacologic therapy for eliminating atrial fibrillation. ObligationsFunding History: Current Active Organizations and Grant Numbers
Center for Cardiovascular Outcomes Research, Initiated in Fiscal Year 2010The purpose of this program is to conduct cardiovascular outcomes research that focuses on patient- and clinician-relevant outcomes of health care and their determinants. The goal is to move clinical evidence into public policy and clinical practice. ObligationsFunding History: Current Active Organizations and Grant Numbers
Childhood Obesity Prevention and Treatment Research (COPTR), Initiated in Fiscal Year 2010See Chapter 11. Clinical Trials. Claudication: Exercise Versus Endoluminal Revascularization, Initiated in Fiscal Year 2005The purpose of this study is to optimize physical functioning, increase activity levels, and reduce CVD risk in older individuals with peripheral artery disease. Investigators are determining whether a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with moderate to severe claudication due to aortoiliac insufficiency. ObligationsFunding History: Current Active Organizations and Grant Numbers
Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004See Chapter 11. Clinical Trials. Consortium of Hospitals Advancing Research on Tobacco (CHART), Initiated in Fiscal Year 2010See Chapter 11. Clinical Trials. Cross Organ Mechanism-Associated Phenotypes for Genetic Analysis of Heart, Lung, Blood, and Sleep Diseases (MAPGen for HLBS) Research Centers, Initiated in Fiscal Year 2011The purpose of this program is to establish a MAPGen consortium of research centers. The consortium seeks to utilize evolving knowledge of cellular and molecular networks to define common mechanism-associated traits across organ systems. The goal is to redefine disease at the level of pathogenetic mechanisms and phenotype individuals based on pathobiology, rather than clinical presentation. This approach will provide the basis for the development of mechanism-based strategies for prevention, diagnosis, and treatment in individual patients. ObligationsFunding History: Current Active Organizations and Grant Numbers
Diabetes Prevention Program Outcomes Study—Phase II, Initiated in Fiscal Year 2009See Chapter 11. Clinical Trials. Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997The purpose of this program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is to evaluate patterns of device usage and the immediate and follow-up outcomes in patients who are undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and designing clinical trials to evaluate competing devices. Twenty-four percent of the patients are from various racial and ethnic minority populations. ObligationsFunding History: Current Active Organization and Grant Number
Early Adult Reduction of Weight Through LifestYle Intervention (EARLY) Trials,* Initiated in Fiscal Year 2009* Formerly known as Targeted Approaches to Weight Control for Young Adults. See Chapter 11. Clinical Trials. Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists are seeking to identify and characterize genes that contribute to CVD in this unique and understudied population. ObligationsFunding History: Current Active Organization and Grant Number
Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006See Chapter 11. Clinical Trials. ISCHEMIA Trial (International Study of Comparative Effectiveness With Medical Invasive Approaches), Initiated in Fiscal Year 2011The purpose of this trial is to define the role of an invasive approach in patients with stable ischemic heart disease and substantial ischemia. Investigators will determine whether cardiac catheterization followed by complete revascularization plus optimal medical therapy is superior to optimal medical therapy alone as the management strategy for patients with moderate-severe ischemia on stress imaging. Cost-effectiveness will also be assessed. ObligationsFunding History: Current Active Organizations and Grant Numbers
Look AHEAD: Action for Health in Diabetes, Initiated in Fiscal Year 2009See Chapter 11. Clinical Trials. Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007See Chapter 11. Clinical Trials. Next Generation Genetic Association Studies, Initiated in Fiscal Year 2011The purpose of this study is to investigate functional aspects of genetic variation in humans by combining cellular reprogramming strategies with molecular profiling or cellular assays, and then integrating the information with existing genotypic and clinical phenotypic data to assess how naturally occurring human genetic variation influences the activities of biological networks in cell-based models of disease. Researchers are seeking to develop the technology needed for high-throughput iPS cell line generation and differentiation and will use the technology to follow up on genomic associations with additional mechanistic information gained from cellular models of disease. ObligationsFunding History: Current Active Organizations and Grant Numbers
NHLBI Cardiac Development Consortium, Initiated in Fiscal Year 2009The purpose of this study is to elucidate the regulatory networks controlling cardiovascular development. A consortium of multidisciplinary research teams will select key regulatory pathways, identify components of the pathways and targets, and disseminate data to the scientific community. Research results may lead to the development of regenerative therapies and tissue engineering approaches. ObligationsFunding History: Current Active Organizations and Grant Numbers
NHLBI Pediatric Cardiac Genomics Consortium, Initiated in Fiscal Year 2009The purpose of this study is to conduct clinical and translational research on the genetic causes of congenital heart disease and the genetic contributions to outcomes in individuals with congenital heart disease. ObligationsFunding History: Current Active Organizations and Grant Numbers
NHLBI Pediatric Translational Consortium Administrative Coordinating Center, Initiated in Fiscal Year 2009The purpose of this Coordinating Center is to provide administrative support for the Cardiovascular Development Consortium and the Pediatric Cardiac Genomics Consortium, monitor multicenter patient recruitment by the Pediatric Cardiac Genomics Consortium, and administer funds to consortium-wide cores. ObligationsFunding History: Current Active Organization and Grant Number
NHLBI Progenitor Cell Biology Consortium Research Hubs, Initiated in Fiscal Year 2009The purpose of this study is to establish virtual research hubs that focus on progenitor cell biology. Investigators are seeking to identify and characterize progenitor cell lineages, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new strategies to address the unique challenges presented by the transplantation of progenitor cells. ObligationsFunding History: Current Active Organizations and Grant Numbers
Obesity Related Behavioral Intervention Trials (ORBIT),* Initiated in Fiscal Year 2009* Formerly known as Translating Basic Behavioral and Social Sciences Discoveries Into Interventions To Reduce Obesity. The purpose of this study is to translate findings from basic research on human behavior into more effective clinical, community, and population interventions to reduce obesity and improve obesity-related behaviors. Investigators are seeking to develop innovative obesity-reducing strategies that are effective in small-scale trials, acceptable to target populations of interest and are ready for testing in large-scale randomized clinical and community trials. Some of the projects are expected to have 50–100 percent participation from minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Pediatric Heart Network, Initiated in Fiscal Year 2006See Chapter 11. Clinical Trials. Pharmacogenetics Research Network, Initiated in Fiscal Year 2001The purpose of this program is to establish a network of multidisciplinary, collaborative research groups to study how genetic variation contributes to interindividual differences in responses to medications. Four studies under this initiative are investigating the pharmacogenetics of heart, lung, and blood diseases. One of the projects has 38 percent minority participation. The Pharmacogenetics Knowledgebase (PharmGKB) has been established to integrate information obtained from pharmacogonomics, phenotypes, and genotypes. ObligationsFunding History: Current Active Organizations and Grant Numbers
Ranolazine in Implantable Defibrillators (RAID) Trial, Initiated in Fiscal Year 2010The purpose of this clinical trial is to determine whether ranolazine will reduce the risk of ventricular arrhythmias and improve survival in high-risk patients who already have an implantable cardiac defibrillator. Currently, very few options are available for treating patients at risk for ventricular arrhythmias—which often leads to death—and ranolazine may be a safe and effective treatment. ObligationsFunding History: Current Active Organizations and Grant Numbers
Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II), Initiated in Fiscal Year 2009The purpose of this study is to determine whether using cardiac computed assisted tomography early in the emergency department triage will enable immediate and safe discharge without further testing of a significant number of patients with acute chest pain. ObligationsFunding History: Current Active Organizations and Grant Numbers
Strong Heart Study, Initiated in Fiscal Year 1988The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. Phase IV expanded the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD. Phase V examined the family study cohort to assess genetic relationships to risk factor change over a 5‑year period and initiated surveillance for cardiovascular morbidity and mortality. ObligationsFunding History: Current Active Organizations and Grant Numbers
Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002The objective of this clinical trial is to continue to follow for 5 more years, patients who were assigned to the first part of the STICH study that sought to determine whether the addition of CABG to intensive medical therapy improves long-term survival of patients with heart failure and left ventricular dysfunction. The original study found no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary endpoint of death from any cause. However, the secondary endpoint related to deaths due to cardiovascular causes showed that patients assigned to CABG had lower rates of death compared with those assigned to medical therapy alone. The extension study (STICHES) will enable investigators to obtain long-term (10-year average) data on survivors from the original cohort. The primary endpoint is all-cause mortality. Secondary endpoints include cardiovascular mortality; cardiovascular morbidity defined by hospitalization for heart failure, myocardial infarction, or need for coronary revascularization procedure; and functional status and symptoms. Approximately 25 percent of the population will come from minority populations. ObligationsFunding History: Current Active Organization and Grant Number
Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials, Initiated in Fiscal Year 2009The purpose of this program is to determine whether therapeutic hypothermia after pediatric cardiac arrest improves outcomes, including survival, in infants and children. Approximately 50 percent of the patients are expected to come from racial and ethnic minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Lung Diseases ProgramAsthma Networks (AsthmaNet), Initiated in Fiscal Year 2009See Chapter 11. Clinical Trials. COPD Clinical Research Network, Initiated in Fiscal Year 2003See Chapter 11. Clinical Trials. Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT), Initiated in Fiscal Year 2011The purpose of this study is to determine whether safe and effective tight glycemic control can sufficiently reduce morbidity and mortality in children with heart and lung failure to justify a low risk of hypoglycemia. ObligationsFunding History: Current Active Organizations and Grant Numbers
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), Initiated in Fiscal Year 2008The purpose of this randomized clinical trial is to assess the efficacy and safety of 7 percent hypertonic saline inhaled twice daily for 48 weeks among infants with CF aged 4 to 15 months at enrollment. Investigators are seeking to determine whether hypertonic saline will improve hyperinflation and obstructive lung disease as measured by infant lung function testing compared with the control agent (isotonic saline). ObligationsFunding History: Current Active Organizations and Grant Numbers
Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls, Initiated in Fiscal Year 2009The purpose of this study is to characterize the microbiome of the lung alone or in combination with the upper airways in HIV-infected individuals and matched HIV-uninfected controls. Investigators will use molecular techniques to identify bacteria, and if possible, other organisms (e.g., viruses, cell-wall deficient organisms, protozoa, and fungi). Data will be used to examine the effects of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, HIV-related respiratory complications, and anti-HIV therapies. ObligationsFunding History: Current Active Organizations and Grant Numbers
Novel Therapies for Lung Diseases—Phase II, Initiated in Fiscal Year 2010See Chapter 11. Clinical Trials. Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment. ObligationsFunding History: Current Active Organization and Grant Number
Prematurity and Respiratory Outcomes Program (PROP), Initiated in Fiscal Year 2010The purpose of this observational clinical study is to investigate hypotheses on the molecular mechanisms that contribute to respiratory disease risk of the premature newborn with the long-term goal of improving outcomes in the first year of life. ObligationsFunding History: Current Active Organizations and Grant Numbers
Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk, Initiated in Fiscal Year 2010The purpose of this study is to create a network of clinical research sites with a Data Coordinating and Analysis Center to develop common research protocols to study the cardiovascular health of women in their first pregnancy and assess the significance of disordered breathing. ObligationsFunding History: Current Active Organization and Grant Number
Randomized Trial of Antenatal Late Preterm Steroids (ALPS), Initiated in Fiscal Year 2010The purpose of this study is to determine whether antenatal corticosteroids can potentially improve lung function and reduce respiratory morbidity in newborn infants who are born in the late preterm period (34–36 weeks). Previous studies have shown that steroids improve lung function in very premature infants. Fifty-five percent of the participants are expected to come from racial and ethnic minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma, Initiated in Fiscal Year 2009The purpose of this randomized clinical trial is to determine whether supplemental vitamin D to increase the level of vitamin D in a pregnant woman will prevent asthma and allergy in her child at age 3 years. Investigators will recruit 870 pregnant women who are in the first trimester of pregnancy and randomize them to one of two treatment arms of a 4-year clinical trial: one arm being treatment with 4,000 international units of vitamin D in addition to typical prenatal vitamins and the other being treatment with typical prenatal vitamins alone. Currently, 80 percent of the participants are from racial and ethnic minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Sedation Management in Pediatric Patients With Acute Respiratory Failure, Initiated in Fiscal Year 2008The purpose of this randomized clinical trial is to test an innovative approach to sedation management that includes team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation; team identification of each patient's trajectory of illness and daily prescription of a sedation goal; use of a nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines; and team feedback on sedation management performance. Investigators have randomized 2,754 critically ill infants and children into two study groups: sedation management intervention and usual care. Forty-five percent of the patients are from racial and ethnic minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Severe Asthma Research Program,* Initiated in Fiscal Year 2011* The Severe Asthma Research Program began in FY 2001 and was funded under the R01 mechanism. The purpose of this study is to define severe asthma at the molecular and cellular levels longitudinally to understand its evolution. Research findings will serve as a rational basis for designing mechanism-based diagnostic, prognostic, and treatment strategies for severe asthma. ObligationsFunding History: Current Active Organizations and Grant Numbers
Study of Asthma and Nasal Steroids (STAN), Initiated in Fiscal Year 2009The purpose of this clinical trial is to determine whether treatment of chronic rhinitis and sinusitis with a nasal steroid improves asthma control. Investigators have randomized 380 patients with poorly controlled asthma and chronic rhinitis and sinusitis to a nasal steroid or matching placebo in addition to their regular asthma treatment. One third of participants are expected to be from minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Study of Soy Isoflavones in Asthma (SOYA), Initiated in Fiscal Year 2009The purpose of this double-blind, randomized controlled trial is to determine whether genistein supplements (soy isoflavone) improves lung function in patients with poorly controlled asthma. The study includes 380 patients with low dietary soy intake, ages 12 years and older, who are taking either inhaled corticosteroids or leukotriene modifiers or both and have poorly controlled asthma. Participants are being randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein, and glycitein) 100 mg daily or to placebo for 6 months. Thirty percent of participants are expected to be from minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Trial of Late Surfactant (TOLSURF) To Prevent Bronchopulmonary Dysplasia, Initiated in Fiscal Year 2009The purpose of this randomized controlled clinical trial is to determine whether late doses of surfactant in addition to iNO administered to extremely low gestational age neonates (< 30 weeks) who require mechanical ventilation between 7 and 14 days of age will increase survival without bronchopulmonary dysplasia. ObligationsFunding History: Current Active Organizations and Grant Numbers
Blood Diseases and ResourcesAcute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT),* Initiated in Fiscal Year 2008* Formerly known as Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT (ATTRACT) Trial. The purpose of this study is to determine whether adjunctive pharmacomechanical catheter-directed thrombolysis (PCDT), which includes intrathrombus administration of recombinant tissue plasminogen activator, can prevent postthrombotic syndrome in patients with symptomatic proximal deep vein thrombosis (DVT). Investigators are comparing the addition of PCDT to optimal standard DVT therapy with optimal standard DVT therapy alone. ObligationsFunding History: Current Active Organizations and Grant Numbers
Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001See Chapter 11. Clinical Trials. Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial, Initiated in Fiscal Year 2008The purpose of this study is to determine the safety and efficacy of low molecular weight heparin (LMWH) in adults with atrial fibrillation who stop warfarin in preparation for surgery. The trial randomly allocated 3,282 patients with atrial fibrillation to either LMWH or placebo before and after surgery. Investigators hypothesize that simply withholding warfarin in a perioperative setting for patients with atrial fibrillation will not meaningfully increase the risk for arterial thromboembolism and will forestall hemorrhagic complications, compared with a strategy using LMWH before and after surgery. One-third of participants are expected to be from minority populations. ObligationsFunding History: Current Active Organizations and Grant Numbers
Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002See Chapter 11. Clinical Trials. NHLBI Centers of Research Program (P50)The Centers of Research Program supports specialized centers that focus on multidisciplinary research and development from basic science to clinical investigation in response to announcements of the programmatic needs of the Institute. The spectrum of activities comprises a multifaceted attack on a specific disease entity or biomedical problem area. NHLBI Centers of Research ProgramObligations (Dollars in Thousands)
NIH Centers for Population Health and Health Disparities (CPHHD) (P50)The purpose of this program is to create centers of transdisciplinary research that will evaluate the multilevel determinants of health disparities and devise interventions to reduce them. ObligationsFiscal Year 2011—$10,168,814 Current Active Organizations and Grant Numbers
Specialized Centers of Clinically Oriented Research (P50)The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasized multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In FY 2002, the NHLBI revised its SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The SCCOR program still requires clinical and basic scientists to work together on a unified theme, but also requires at least 50 percent of the projects to be clinical. The SCOR program ended in FY 2008. A description of the SCCORs supported by the Institute follows. Heart Diseases ProgramVascular Injury, Repair, and RemodelingThe purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions that will enable basic science findings to be more rapidly translated into clinical applications. Major goals of the program are to stimulate interdependent clinical and multidisciplinary basic research projects that investigate molecular and cellular mechanisms of vascular injury, repair, and remodeling; promote patient-oriented research that will improve our ability to prevent, detect, characterize, manage, and treat vascular diseases; and develop the skills and research capabilities of new clinical investigators. ObligationsFiscal Year 2011—$1,759,969 Current Active Organization and Grant Number
Lung Diseases ProgramChronic Obstructive Pulmonary DiseaseThe purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD. The program includes a broad spectrum of basic and clinical research that encompasses animal models of COPD pathogenesis; human proteomic, genetic, and genomic investigations; disease phenotypes classification; and the development of new therapeutic interventions. ObligationsFiscal Year 2011—$8,775,106 Current Active Organizations and Grant Numbers
Pulmonary Vascular DiseaseThe objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease. ObligationsFiscal Year 2011—$4,660,206 Current Active Organizations and Grant Numbers
Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases (CADET) (P50)The purpose of this program is to accelerate the development of novel agents for the diagnosis and treatment of lung diseases and sleep disordered breathing through the use of rational strategies based on fundamental pathobiologic processes. CADET I provides opportunities to explore potential targets for validation to determine which are amenable for development of mechanism-based modalities for direct clinical application in the prevention, diagnosis, and treatment of pulmonary diseases and sleep disordered breathing. ObligationsFiscal Year 2011—$9,000,370 Current Active Organizations and Grant Numbers
Basic and Translational Research Program (U54)The NHLBI reconfigured the Comprehensive Sickle Cell Centers program into a Basic and Translational Research Program (BTRP). The Program emphasizes fundamental investigations and their translation into initial studies in humans, as well as community translation to promote evidence-based clinical practice. The BTRP continues to support the Sickle Cell Disease Scholars program for the career development of young investigators and the Summer-for-Sickle Cell-Science program for research training and mentoring of high-school students. These components are part of a larger effort by the NHLBI to prepare the next generation of scientists to advance the field of SCD research. ObligationFiscal Year 2011—$5,901,312 Current Active Organizations and Grant Numbers
Cardiac Translational Research Implementation Program (C-TRIP) (P20)The C-TRIP program was initiated in FY 2010 to accelerate the translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias. The program consists of two stages. Stage 1 focuses on planning and developing clinical trials to determine the safety and efficacy of interventions to be conducted during Stage 2 of the overall program. Stage 2 studies will be supported by the P50 mechanism. ObligationFiscal Year 2011—$8,592,776 Current Active Organizations and Grant Numbers
Centers for AIDS Research (P30) ProgramThe NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups. ObligationsFiscal Year 2011—$3,333,747 Current Active Organizations and Grant Numbers
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Twitter
Facebook
YouTube